Back to Authors

Al-Janabi, Omar M

0000-0003-2208-4308

Mayo Clinic

Department of Neurology, Baptist Health, Lexington, KY 40503, USA.

Citations 2

Current Stroke Solutions Using Artificial Intelligence: A Review of the Literature
Al‐Janabi, Omar , Refaei, Amro El, Elgazzar, Tasnim , Mahmood, Yamama M., Bakir, Danah, Gajjar, Aryan, Alateya, Aysha, Jha, Saroj Kumar , Ghozy, Sherief , Kallmes, David F. , Brinjikji, Waleed , Al-Janabi, Omar M , Ghozy, Sherief , Gajjar, Aryan

Brain Sciences | November 26, 2024 | Volume: 14 | Issue: 12 | Pages: 1182

10.3390/brainsci14121182 Get It

Introduction: In recent years, artificial intelligence (AI) has emerged as a transformative tool for enhancing stroke diagnosis, aiding treatment decision making, and improving overall patient care. Leading AI-driven platforms such as RapidAI, Brainomix®, and Viz.ai have been developed to assist healthcare professionals in the swift and accurate assessment of stroke patients. Methods: Following the PRISMA guidelines, a comprehensive systematic review was conducted using PubMed, Embase, Web of Science, and Scopus. Characteristic descriptive measures were gathered as appropriate from all included studies, including the sensitivity, specificity, accuracy, and comparison of the available tools. Results: A total of 31 studies were included, of which 29 studies focused on detecting acute ischemic stroke (AIS) or large vessel occlusions (LVOs), and 2 studies focused on hemorrhagic strokes. The four main tools used were Viz.ai, RapidAI, Brainomix®, and deep learning modules. Conclusions: AI tools in the treatment of stroke have demonstrated usefulness for diagnosing different stroke types, providing high levels of accuracy and helping to make quicker and more precise clinical judgments.
Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: A systematic review and meta‐analysis
Al‐Janabi, Omar , Toruno, Michelle A. , Mahmood, Yamama M., Ghozy, Sherief , Yaghi, Shadi , Kallmes, David F. , Al-Janabi, Omar M , Jazayeri, Seyed Behnam , Ghozy, Sherief , Yaghi, Shadi , Rabinstein, Alejandro A.

Annals of Clinical and Translational Neurology | October 29, 2024 | Volume: 11 | Issue: 12 | Pages: 3310-3319

10.1002/acn3.52239 Get It

AbstractObjectiveAbout 25% of patients with acute ischemic stroke (AIS) present within the intravenous thrombolytic (IVT) therapeutic window of <4.5 h. This study is to elucidate the safety and efficacy of IVT in the extended therapeutic window (ETW) in patients with AIS.MethodsUsing PRISMA guidelines, a systematic review was conducted using PubMed, Embase, and Scopus. A rigorous risk of bias assessment was conducted using the RoB2 tool. Rates of excellent and good functional outcome (mRS 0–1 and mRS 0–2) at 90 days, symptomatic intracranial hemorrhage (sICH), and mortality at 90 days were pooled using generalized linear mixed model and compared with controls. Meta‐analyses were conducted employing random‐effect models with risk ratio (RR) and 95% confidence intervals (CIs). Subgroup analysis was performed to assess the effect of imaging modalities used for patient selection.ResultsEight randomized controlled trials (n = 2221, 59% male) were included. At 90 days IVT showed higher rates of functional recovery: mRS 0–1: RR 1.21 95% CI 1.1–1.34, p < 0.001, and mRS 0–2: RR 1.11 95% CI 1.03–1.18, p = 0.004. Rate of mortality at 90 day was not different between groups: RR 1.17 95% CI 0.93–1.48, p = 0.17. However, the rate of sICH was higher among IVT group: RR 2.93 95% CI 1.53–5.6, p = 0.001. Subgroup analysis showed higher mRS 0–1 among patients who were selected based on perfusion imaging (p < 0.05).InterpretationThe use of IVT in AIS in ETW is beneficial especially with the use of perfusion imaging for patients' selection.